A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant has been cleared for sale in the US as a treatment for ovarian, fallopian ...
Chemotherapy can make food taste metallic, bland, or unpleasant, turning everyday eating into a clinical challenge that ...
Artificial intelligence (AI) is emerging as a powerful force in breast cancer research, but the future of personalized care will not be written by ...
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration ...
Background Cancer survivors often face the risk of developing heart failure (HF) as a result of their previous cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results